Pharmaceutical Executive
How R&D organizations can leverage FDA’s final guidance on pre-approval information exchange (PIE) to engage with payers prior to approval and launch.
Dean Hakanson, Jon Gonzales, and Tara Alire
Advertisement
Dean Hakanson, Jon Gonzales, and Tara Alire
Articles by Dean Hakanson, Jon Gonzales, and Tara Alire
R&D organizations can leverage FDA’s final guidance on pre-approval information exchange, otherwise known as PIE, to engage with payers prior to regulatory approval and commercial launch.
Advertisement
Latest Updated Articles
- Using FDA’s ‘PIE’ Recipe to Enhance Patient Access
August 1st 2019
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5